Other News To Note
Wednesday, January 26, 2011
Oxford BioTherapeutics, of Oxford, UK, said that Sanofi-Aventis SA, of Paris, acquired an exclusive worldwide license to one of OBT's internal preclinical antibody programs.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.